Formpipe - Business as Usual
2020-08-20 08:05:00
Redeye remains neutral to Formpipe following a better Q2 than we expected. Both EBIT and the forward-looking sales numbers beat our estimates, and management sees a solid Private segment in H2 2020. We raise our 2021 EBITA forecast and our Base case slightly.
Read more and download the Research Update
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/